Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials

Ziemssen, F.; Feltgen, N.; Holz, FG.; Guthoff, R.; Ringwald, A.; Bertelmann, T.; Wiedon, A.; Korb, C.

doi:10.1186/s12886-017-0401-y

Table 4 Patient demographics for OCEAN and selected randomized controlled trials in the indication retinal vein occlusion

From: Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials

Study	Treatment group	N	Age mean ± SD (years)	Age range (years)	Gender, n (%)		Time since first diagnosis of RVO mean ± SD (months)	Time since first diagnosis of RVO median [range] (months)	Baseline VA
Study	Treatment group	N	Age mean ± SD (years)	Age range (years)	male	female	Time since first diagnosis of RVO mean ± SD (months)	Time since first diagnosis of RVO median [range] (months)	ETDRS letters analogue (mean ± SD)^a
Indication BRVO
OCEAN^b BRVO patients	Ranibizumab 0.5 mg	204	71.2 ± 10.0	39.2-92.7	85 (41.7)	119 (58.3)	6.30 ± 16.35 ^c,d	1.63 [0–127] ^c,d	55.9 ± 20.9
BRAVO [50]	Sham injections (6 months)	132	65.2 ± 12.7	26-89	74 (56.1)	58 (43.9)	3.7 ± 3.7	2 [0–16]	54.7 ± 12.2
	Ranibizumab 0.3 mg	134	66.6 ± 11.2	43-90	67 (50.0)	67 (50.0)	3.6 ± 4.1	2 [0–35]	56.0 ± 12.1
	Ranibizumab 0.5 mg	131	67.5 ± 11.8	41-91	71 (54.2)	60 (45.8)	3.3 ± 3.1	2 [0–13]	53.0 ± 12.5
VIBRANT [51]	Laser	90	63.9 ± 11.4	n. a.	n. a.	36 (40.0)	1.4 ± 1.3 ^d	n. a.	57.7 ± 11.3
VIBRANT [51]	Aflibercept 2 mg	91	67.0 ± 10.4	n. a.	n. a.	47 (51.6)	1.4 ± 1.4 ^d	n. a.	58.6 ± 11.4
Indication CRVO
OCEAN^b CRVO patients	Ranibizumab 0.5 mg	121	70.3 ± 11.5	26.7-91.9	57 (47.1)	64 (52.9)	3.78 ± 6.49 ^c,d	1.44 [0–38] ^c,d	43.7 ± 25.0
CRUISE [52]	Sham injections	130	65.4 ± 13.1	20-91	72 (55.4)	58 (44.6)	2.9 ± 2.9	2 [0–14]	49.2 ± 14.7
	Ranibizumab 0.3 mg	132	69.7 ± 11.6	38-90	71 (53.8)	61 (46.2)	3.6 ± 3.2	2 [0–12]	47.4 ± 14.8
	Ranibizumab 0.5 mg	130	67.6 ± 12.4	40-91	80 (61.5)	50 (38.5)	3.3 ± 3.7	2 [0–27]	48.1 ± 14.6
COPERNICUS [53]^e	Aflibercept 2 mg 2q4, then PRN	114	65.5 ± 13.57	n. a.	69 (61)	45 (39)	2.73 ± 3.09	n. a.	50.7 ± 13.9
COPERNICUS [53]^e	Sham injections 2q4, then Aflibercept 2 mg PRN	73	67.5 ± 14.29	n. a.	38 (52)	35 (48)	1.88 ± 2.19	n. a.	48.9 ± 14.4
GALILEO [54]	VEGF Trap-Eye (Aflibercept) 2q4	103	59.9 ± 12.4	n. a.	58 (56.3)	45 (43.7)	2.6 ± 2.9^d	n. a.	53.6 ± 15.8
GALILEO [54]	Sham injections	68	63.8 ± 13.3	n. a.	37 (54.4)	31 (45.6)	2.9 ± 2.6^d	n. a.	50.9 ± 15.4

^aMethod of measuring baseline VA not always explained in sources. Direct comparisons of VA results may not be reliable
^bMissing values in OCEAN: time since first diagnosis of RVO: 3 in BRVO, 3 in CRVO; baseline VA: 1 in BRVO, 3 in CRVO
^cTime since diagnosis until first injection in OCEAN
^dResults converted to months (originally in days)
^eMissing values in COPERNICUS: Time since first diagnosis of RVO: 1 patient (in treatment group “Aflibercept 2 mg 2q4, then PRN”)
Abbreviations: 2q4: every 4 weeks for 24 weeks; BRVO: branch retinal vein occlusion; CRVO: central retinal vein occlusion; ETDRS: Early Treatment Diabetic Retinopathy Study; N: total number of patients; n: number of patients; n. a.: data not available in source; PRN: pro re nata (as needed); RVO: retinal vein occlusion; SD: standard deviation; VA: visual acuity

Back to article page

ISSN: 1471-2415

Contact us

General enquiries: journalsubmissions@springernature.com

BMC Ophthalmology

Contact us